Norway· NO-ID_364A8270-9A97-4091-AD49-859565D232EE
Enjaymo
A sutimlimab product containing sutimlimab, registered in Norway by Recordati Rare Diseases. The same ATC class is registered in 9 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Sutimlimab is registered in 9 of 19 countries.
Countries holding a registration under ATC L04AJ04 (sutimlimab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Sutimlimab · ATC L04AJ04
9 / 19 countries
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Sutimlimab
- Manufacturer
- Recordati Rare Diseases
- Country
- Norway (NO)
- ATC code
- L04AJ04
- ATC class
- Sutimlimab
- Defined daily dose
- 0.46 g, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_364A8270-9A97-4091-AD49-859565D232EE
- no_varenummer0333911 x 22NOK 14835.6
- gtin4150180088353
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sutimlimab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandEnjaymo 1100 mg/22 ml, InfusionslösungRECORDATI AG
- CzechiaENJAYMORecordati Rare Diseases, Puteaux
- FinlandEnjaymoRecordati Rare Diseases
- IrelandEnjaymo 50 mg/mL solution for infusionRecordati Rare Diseases
- IcelandEnjaymoRecordati Rare Diseases
- PolandEnjaymoSanofi B.V.
- BelgiumEnjaymo 50 mg/mlRecordati Rare Diseases
- SwedenEnjaymo 50 mg/mL Infusionsvätska, lösningRecordati Rare Diseases
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Enjaymo
- Liechtenstein · Enjaymo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7b37361f-92c1-412f-91d7-215d0c7bf086 GET /v1/drugs/7b37361f-92c1-412f-91d7-215d0c7bf086?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Sutimlimab",
"merkevare_id": "ID_364A8270-9A97-4091-AD49-859565D232EE",
"name_form_strength": "Enjaymo inf, oppl 50 mg/ml",
"prescription_group": "C"
}See everything about sutimlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.